[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594356":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":26,"responsibleParty":42,"collaborators":26,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":26,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":26,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":26,"overallStatus":63,"whyStopped":26,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":26},{"fullName":5,"class":6},"Tianjin Medical University General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oliceridine group","EXPERIMENTAL","Administer a loading dose of 0.03 mg\u002Fkg intravenously 20-30 minutes before the end of surgery. Postoperative PCA pump configuration: 0.6 mg\u002Fkg oxycodone diluted with normal saline to a total volume of 100 mL, with a background infusion rate of 2 mL\u002Fh, PCA bolus dose of 0.5 mL per injection, lockout interval of 15 minutes, and treatment duration of 48 hours.",[13],"Drug: Oliceridine",{"label":15,"type":16,"description":17,"interventionNames":18},"Sufentanil Group","ACTIVE_COMPARATOR","Administer a loading dose of 0.1 μg\u002Fkg intravenously 20-30 minutes before the end of surgery. Postoperative PCA pump configuration: 2 μg\u002Fkg sufentanil diluted with normal saline to a total volume of 100 mL, with a background infusion rate of 2 mL\u002Fh, PCA bolus dose of 0.5 mL per injection, lockout interval of 15 minutes, and treatment duration of 48 hours.",[19],"Drug: Sufentanil",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Oliceridine","postoperative patient-controlled analgesia (PCA)",[9],null,{"type":22,"name":28,"description":28,"armGroupLabels":29,"otherNames":26},"Sufentanil",[15],[31],{"name":32,"affiliation":5,"role":33},"Yang Jiao, Doctor","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":26,"email":38},"CONTACT","+86 159 0029 2506","jiaoxiuxiu1987@163.com",{"name":40,"role":36,"phone":26,"phoneExt":26,"email":41},"Yonghao Yu, Doctor","yuyonghaoemail@126.com",{"type":33,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Yang Jiao","Associate Chief Physician","100594356","phase-4-the-effect-of-oliceridine-patient-controlled-intravenous-analgesia-on-postoperative-chronic-pain-after-video-assisted-thoracoscopic-lobectomy-100594356",false,"NCT07018375","The Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lobectomy","Inclusion Criteria:\n\n* ① Age 18-75 years, ASA physical status I-III, BMI 18-30 kg\u002Fm²;\n\n  * Scheduled for unilateral video-assisted thoracoscopic surgery (VATS) lung resection, including wedge resection, segmentectomy, lobectomy, or radical resection for lung cancer;\n\n    * Preoperative pain score \\\u003C1 on the Numeric Rating Scale (NRS);\n\n      * Ability to understand the study objectives and procedures, with voluntary informed consent obtained;\n\n        * Expected postoperative recovery in the general ward setting.\n\nExclusion Criteria:\n\n* ① History of chronic pain or long-term analgesic use prior to surgery;\n\n  * Previous ipsilateral thoracic surgery;\n\n    * Prior neoadjuvant radiotherapy or chemotherapy;\n\n      * Severe cardiovascular or cerebrovascular disease, or hepatic\u002Frenal dysfunction (ALT\u002FAST \\>3× upper limit of normal; eGFR \\\u003C60 mL\u002Fmin\u002F1.73m²);\n\n        * Concurrent malignancy or active infection;\n\n          * Pre-existing psychiatric disorders or communication barriers precluding study participation;\n\n            * Known hypersensitivity to study medications (opioids, adjuvant analgesics, anesthetics, or antiemetics);\n\n              * Any condition deemed unsuitable for study participation by the investigator","ALL","18 Years","75 Years",{"count":55,"type":56},320,"ESTIMATED","INTERVENTIONAL",[59],"PHASE4","The primary objective is to evaluate the impact of oliceridine versus sufentanil for perioperative analgesia on the incidence of chronic postsurgical pain (CPSP) in patients undergoing video-assisted thoracoscopic surgery.",[62],"Chronic Postsurgical Pain","NOT_YET_RECRUITING","2026-01-05",{"date":66,"type":67},"2026-01-06","ACTUAL",{"date":66,"type":56},{"date":70,"type":56},"2027-04-30",{"name":5,"class":6}]